Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib and Iguratimod in Rheumatoid Arthritis
NCT04928066Phase 4Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of iguratimod in rheumatoid arthritis (RA), sponsored by Qilu Hospital of Shandong University. Started Mar 2020; status: completed.
02
Drugs
iguratimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04928066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928066.